19.01.2011 • News

Amgen To Sell California Drug Plant To Boehringer

Amgen, the world's biggest maker of biotechnology drugs, plans to sell its Fremont, Calif., development and manufacturing plant to Germany's Boehringer Ingelheim, the companies said on Tuesday. Financial terms were not disclosed.

Amgen, based in Thousand Oaks, Calif., said the 100,000-square-foot plant employs about 360 people who will become employees of Boehringer.

The German company, which has manufactured Amgen drugs on a contract basis for more than 10 years, said the deal will allow it to expand contract manufacturing, process development and development of active ingredients based on biologics.

The deal is expected to close in March.

Amgen obtained the Fremont facility in its 2006 acquisition of antibody drug maker Abgenix.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.